U.S. FDA Approves Pfizer ’s Xeljanz (tofacitinib) for the Treatment of Active Ankylosing Spondylitis

NEW YORK--(BUSINESS WIRE) December 14, 2021 -- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Xeljanz® / Xeljanz® XR (tofacitinib) for...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news